Effects of multiple treatments with stem cell therapy in patients with multiple sclerosis

IF 2.9 3区医学 Q2 CLINICAL NEUROLOGY Multiple sclerosis and related disorders Pub Date : 2024-10-15 DOI:10.1016/j.msard.2024.105944

Liding Fan , Yunfei Zhang , Shuo Huang , Jie Chen , Junying Wang , Furen Meng , Jiarui Zhang , Qingjie Xue

{"title":"Effects of multiple treatments with stem cell therapy in patients with multiple sclerosis","authors":"Liding Fan , Yunfei Zhang , Shuo Huang , Jie Chen , Junying Wang , Furen Meng , Jiarui Zhang , Qingjie Xue","doi":"10.1016/j.msard.2024.105944","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>This study was to evaluate the effectiveness of stem cell therapies (AHSCT: autologous hematopoietic stem cell transplantation and MSCs: mesenchymal stem cells) compared to non-stem cell therapies in multiple sclerosis (MS) patients.</div></div><div><h3>Design</h3><div>Clinical trials to investigate the therapeutic effects of stem cells therapy was searched by PubMed, Embase, Web of Science, and the Cochrane Library. The Cochrane Risk of Bias Assessment Tool and data analysis software will be applied.</div></div><div><h3>Results</h3><div>Data were collected between the earliest available date and August 2023. Ten studies were included, with a sample size of 5288 used in the studies. Results showed that human umbilical cord-derived mesenchymal stem cells reduced the Annualized Relapse Rate (SUCRA: 70.9 %) and Expanded Disability Status Scale (SUCRA: 77.1 %) of MS patients, AHSCT reduced mortality rate (SUCRA: 69.8 %), autologous peripheral blood stem cell transplantation (APBSCT) reduced recurrence rate (SUCRA: 86.7 %) and improved No Evidence of Disease Activity-3 (SUCRA: 92.8 %).</div></div><div><h3>Conclusion</h3><div>At present, AHSCT and MSCs have been demonstrated to reduce the recurrence rate of multiple sclerosis and improve disability, particularly in the case of hUC-MSCs. However, APBSCT and AHSCT in the context of the NEDA-3 criteria have not yielded the desired outcomes.</div></div>","PeriodicalId":18958,"journal":{"name":"Multiple sclerosis and related disorders","volume":"92 ","pages":"Article 105944"},"PeriodicalIF":2.9000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis and related disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2211034824005200","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study was to evaluate the effectiveness of stem cell therapies (AHSCT: autologous hematopoietic stem cell transplantation and MSCs: mesenchymal stem cells) compared to non-stem cell therapies in multiple sclerosis (MS) patients.

Design

Clinical trials to investigate the therapeutic effects of stem cells therapy was searched by PubMed, Embase, Web of Science, and the Cochrane Library. The Cochrane Risk of Bias Assessment Tool and data analysis software will be applied.

Results

Data were collected between the earliest available date and August 2023. Ten studies were included, with a sample size of 5288 used in the studies. Results showed that human umbilical cord-derived mesenchymal stem cells reduced the Annualized Relapse Rate (SUCRA: 70.9 %) and Expanded Disability Status Scale (SUCRA: 77.1 %) of MS patients, AHSCT reduced mortality rate (SUCRA: 69.8 %), autologous peripheral blood stem cell transplantation (APBSCT) reduced recurrence rate (SUCRA: 86.7 %) and improved No Evidence of Disease Activity-3 (SUCRA: 92.8 %).

Conclusion

At present, AHSCT and MSCs have been demonstrated to reduce the recurrence rate of multiple sclerosis and improve disability, particularly in the case of hUC-MSCs. However, APBSCT and AHSCT in the context of the NEDA-3 criteria have not yielded the desired outcomes.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

干细胞疗法对多发性硬化症患者的多重治疗效果。

研究目的本研究旨在评估干细胞疗法（AHSCT：自体造血干细胞移植和MSCs：间充质干细胞）与非干细胞疗法相比，对多发性硬化症（MS）患者的疗效：设计：通过PubMed、Embase、Web of Science和Cochrane图书馆搜索研究干细胞疗法疗效的临床试验。应用Cochrane偏倚风险评估工具和数据分析软件：数据收集时间为最早可用日期至 2023 年 8 月。共纳入 10 项研究，研究样本量为 5288 个。结果显示，人脐间质干细胞降低了多发性硬化症患者的年复发率（SUCRA：70.9%）和扩展残疾状态量表（SUCRA：77.1%），AHSCT降低了死亡率（SUCRA：69.AHSCT降低了死亡率（SUCRA：69.8%），自体外周血干细胞移植（APBSCT）降低了复发率（SUCRA：86.7%），改善了无疾病活动证据-3（SUCRA：92.8%）：结论：目前，AHSCT和间充质干细胞已被证明可降低多发性硬化症的复发率并改善残疾状况，尤其是在使用hUC-间充质干细胞的情况下。然而，根据 NEDA-3 标准进行的 APBSCT 和 AHSCT 并未取得预期效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Multiple sclerosis and related disorders CLINICAL NEUROLOGY-

CiteScore

5.80

自引率

20.00%

发文量

814

审稿时长

66 days

期刊介绍： Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. The primary aim of this new journal is the rapid publication of high quality original research in the field. Important secondary aims will be timely updates and editorials on important scientific and clinical care advances, controversies in the field, and invited opinion articles from current thought leaders on topical issues. One section of the journal will focus on teaching, written to enhance the practice of community and academic neurologists involved in the care of MS patients. Summaries of key articles written for a lay audience will be provided as an on-line resource. A team of four chief editors is supported by leading section editors who will commission and appraise original and review articles concerning: clinical neurology, neuroimaging, neuropathology, neuroepidemiology, therapeutics, genetics / transcriptomics, experimental models, neuroimmunology, biomarkers, neuropsychology, neurorehabilitation, measurement scales, teaching, neuroethics and lay communication.